Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾Æ¿¡¼­ ¼ºÀåÈ£¸£¸ó Ä¡·á Áß ¹ß»ýÇÑ Æ¯¹ßÀ¯µÎºÎÁ¾°ú °áÇÕµÈ °¡¼ºÀ¯µÎºÎÁ¾ Pseudopapilledema Combined with Idiopathic Papilledema in a Child Receiving Growth Hormone Treatment

´ëÇѾȰúÇÐȸÁö 2020³â 61±Ç 12È£ p.1548 ~ 1552
ÀÌÈñö, ¹ÚÂù±Ý,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÈñö ( Lee Hee-Chul ) 
Maryknoll Medical Center Department of Ophthalmology

¹ÚÂù±Ý ( Park Chan-Keum ) 
Maryknoll Medical Center Department of Ophthalmology

Abstract

¸ñÀû: ¼ºÀåÈ£¸£¸ó Ä¡·á Áß Æ¯¹ßÀ¯µÎºÎÁ¾°ú °áÇÕµÈ °¡¼ºÀ¯µÎºÎÁ¾ÀÌ ¹ß»ýÇÑ ¼Ò¾Æ ȯÀÚ 1¿¹¸¦ º¸°íÇÏ°íÀÚ ÇÑ´Ù.

Áõ·Ê¿ä¾à: Ưº°ÇÑ ±âÀúÁúȯÀÌ ¾ø´Â 11¼¼ ¿©¾Æ°¡ 3°³¿ù°£ ¼ºÀåÈ£¸£¸ó Ä¡·á¸¦ ¹Þ°í ¹ß»ýÇÑ ÀϽÃÀû ½Ã¾ßÈ帲, ¾Ï¼øÀÀ Àå¾Ö ¹× ¹«±â·Â°¨À» ÁּҷΠŸ¿ø¿¡ ³»¿øÇÏ¿´´Ù. ÀÌÇÐÀû °Ë»ç»ó 20/20¿¡¼­ 20/25·ÎÀÇ ½Ã·ÂÀúÇÏ¿Í ¾ÈÀú°Ë»ç¿¡¼­ ¾ç¾È¿¡ À¯µÎºÎÁ¾ÀÌ ¹ß°ßµÇ¾ú°í, Áï½Ã ¼ºÀåÈ£¸£¸ó Ä¡·á¸¦ Áß´ÜÇÏ¿´´Ù. 4ÁÖ ÈÄ, º»¿ø¿¡ ¹æ¹®ÇÏ¿´À» ¶§ ¾ÈÀú°Ë»ç»ó À¯µÎºÎÁ¾Àº ¾ç¾È¿¡ ºñ½ÁÇÑ Á¤µµ·Î °üÂûµÇ¾ú°í ¿ì¾ÈÀÇ °æ¹ÌÇÑ Àû·Ï »ö°¢ÀÌ»ó¸¸ º¸¿´´Ù. ¼ºÀåÈ£¸£¸ó Åõ¿©·Î ÀÎÇÑ Æ¯¹ßÀ¯µÎºÎÁ¾°ú °áÇÕµÈ °¡¼ºÀ¯µÎºÎÁ¾À» ÀǽÉÇÏ¿´°í, ¼ºÀåÈ£¸£¸ó Åõ¿© Áß´ÜÀ» Áö¼ÓÇϸç À¯µÎºÎÁ¾¿¡ ´ëÇÏ¿© °æ°ú °üÂûÇϱâ·Î ÇÏ¿´´Ù.

°á·Ð: ¼ºÀåÈ£¸£¸ó Ä¡·á Áß ¾ÈÀú°Ë»ç»ó ¾ç¾È À¯µÎºÎÁ¾ÀÌ °üÂûµÇ¾î, ¼ºÀåÈ£¸£¸ó Ä¡·á¸¦ Áß´ÜÇÏ¿´°í, 4ÁÖ ÈÄ ½Ã·ÂÀå¾Ö´Â È£ÀüµÇ¾úÁö¸¸ °æµµÀÇ À¯µÎºÎÁ¾°ú °áÇÕµÈ °¡¼ºÀ¯µÎºÎÁ¾ÀÌ ±×´ë·Î ³²¾ÆÀִ ȯÀÚ¸¦ º¸°íÇÏ´Â ¹ÙÀÌ´Ù.

Purpose: We report a case of pseudopapilledema combined with idiopathic papilledema in a pediatric patient receiving growth hormone treatment.

Case summary: An 11-year-old girl without any underlying disease presented with bilateral transient visual obscurations, a dark-adaptation disorder, and helplessness that developed while she had been on growth hormone therapy for 3 months at a local clinic. Reduced visual acuity (from 20/20 to 20/25) was observed on physical examination and bilateral optic disc edema on fundus examination, growth hormone was immediately discontinued. Four weeks later, fundus examination revealed papilledema of both eyes with mild red-green dyschromatopsia. Recombinant growth hormone-associated idiopathic papilledema combined with pseudopapilledema was suspected. Although growth hormone, had been discontinued, we scheduled further observation of the papilledema.

Conclusions: Papilledema was observed on fundus examination during growth hormone treatment and four weeks after discontinuation thereof. The symptoms improved, but mild papilledema combined with pseudopapilledema remained.

Å°¿öµå

Growth hormone; Papilledema

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS